Exelixis Profile

Exelixis Patent Grants

Crystalline solid forms of N-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl} -n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Patent Number 11760726 - September 19, 2023

The invention relates to novel crystalline solid forms of the chemical compound…

Compounds for the treatment of kinase-dependent disorders

Patent Number 11673897 - June 13, 2023

Disclosed herein are compounds of Formula I?. Compounds of Formula I? inhibit, regulate and/or modulate kinase receptor, particularly Axl and…

Method of treating cancer

Patent Number 11612597 - March 28, 2023

This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases,…

MEK inhibitors and methods of their use

Patent Number 11597699 - March 7, 2023

Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are…

Cabozantinib dosage form and use in the treatment of cancer

Patent Number 11564915 - January 31, 2023

This invention relates to a dosage form of cabozantinib and a method of employing the dosage form to treat cancer.

Exelixis Patent Applications

MULTISPECIFIC BINDING AGENTS AND USES THEREOF

Application Number 20240010751 - January 11, 2024

The present disclosure provides multispecific binding agents (e.g., antibodies, such as bispecific antibodies) that have a first binding…

MULTISPECIFIC BINDING AGENTS AND USES THEREOF

Application Number 20240010751 - January 11, 2024

The present disclosure provides multispecific binding agents (e.g., antibodies, such as bispecific antibodies) that have a first binding…

CD47 BINDING AGENTS AND USES THEREOF

Application Number 20230357391 - November 9, 2023

The present disclosure provides CD47 binding agents (e.g., antibodies, including multispecific antibodies, such as bispecific antibodies) and…

PD-L1 BINDING AGENTS AND USES THEREOF

Application Number 20230303699 - September 28, 2023

The present disclosure provides PD-L1 binding agents (e.g., antibodies, including multispecific antibodies, such as bispecific antibodies) and…

ANTI-ROR ANTIBODY CONSTRUCTS

Application Number 20210155692 - May 27, 2021

Anti-ROR antibody constructs, pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.

Exelixis Federal Litigation Filings

YOUNG v. EXELIXIS, INC.

Pennsylvania Eastern District Court - December 20, 2023

Exelixis, Inc. v. Cipla Ltd. et al

Delaware District Court - March 16, 2023

Exelixis, Inc. v. Zydus Pharmaceuticals USA Inc.

Delaware District Court - March 1, 2023

Exelixis, Inc. v. Teva Pharmaceutical Industries Limited et al

Delaware District Court - September 2, 2022

Exelixis, Inc. v. MSN Laboratories Private Limited et al

Delaware District Court - February 23, 2022

Exelixis Federal District Court Decisions

Exelixis, Inc. v. MSN Laboratories Private Limited et al

Delaware District Court - April 20, 2022

MEMORANDUM ORDER: I DENY the Daubert motion. (D.I. 257). The issue could be appropriate for a motion in limine, although based on what is…

Exelixis, Inc. v. Honorable David J. Kappos

Virginia Eastern District Court - January 28, 2013

MEMORANDUM OPINION in re 16 Motion for Summary Judgment and 13 Motion for Summary Judgment. Signed by District Judge Leonie M. Brinkema…

Exelixis State Court Decisions

Exelixis, Inc. v. MSN Laboratories Private Limited et al

Delaware Delaware District Court - January 19, 2023

TRIAL OPINION: MSN failed to prove by clear and convincing evidence that claims 5 of the '473 patent is invalid as obvious. Exelixis…

Artt v. Exelixis US LLC

Texas Texas Northern District Court - March 28, 2022

MEMORANDUM OPINION AND ORDER granting 19 Motion for Summary Judgment. (Ordered by Senior Judge A. Joe Fish on 3/28/2022) (jmg)